Bristol-Myers Squibb(US:BMY) 21世纪经济报道·2025-10-16 07:55Core Viewpoint - The article emphasizes the significant advancements in cancer treatment, particularly through immunotherapy, which has made the five-year survival rate a more attainable goal for patients. The recognition of these advancements by the Nobel Prize highlights the importance of ongoing research in this field [1][2]. Group 1: Immunotherapy Breakthroughs - The CheckMate series of studies has laid the foundation for current immunotherapy practices, with the PD-1 inhibitor, Nivolumab, being a key development [2][4]. - The year 2025 marks the 43rd year of the company's presence in China and the fifth year of its "China 2030 Strategy," focusing on integrating global research with local patient needs [2][4]. Group 2: Focus on Gastrointestinal Tumors - Gastrointestinal tumors have a high incidence in China, and the company has made significant contributions to this area, particularly through the CheckMate-649 study, which has provided long-term survival benefits for advanced gastric cancer patients [5][6]. Group 3: Expanding Treatment Applications - The company has been proactive in exploring the role of immunotherapy in early-stage cancer, with Nivolumab receiving approvals for four early-stage indications in China, leading to improved treatment outcomes [7][8]. - The CheckMate-816 study has demonstrated the effectiveness of the "immunotherapy + chemotherapy" approach in early non-small cell lung cancer, changing clinical practices and offering hope for a cure [7][8]. Group 4: Long-term Evidence and Standards - The company emphasizes the importance of long-term follow-up studies, such as those from CheckMate-649 and CheckMate-816, which have confirmed significant survival benefits and established clinical standards [9][10]. Group 5: Accessibility Initiatives - The company has worked to enhance the accessibility of immunotherapy through collaborations with commercial insurance and patient assistance programs, benefiting over 40,000 patients [11][12]. - The introduction of a new commercial health insurance directory aims to include innovative drugs, further improving patient access to treatments [12][13]. Group 6: Future Directions - The company plans to continue its focus on immunotherapy while exploring new treatment combinations and expanding its pipeline with innovative therapies, including targeted protein degradation platforms [17][19]. - The integration of Chinese patient data into global research is expected to enhance the relevance of new therapies for local populations [21][22]. Group 7: Commitment Beyond Five Years - The company is committed to ongoing scientific innovation and addressing local needs as part of its "China 2030 Strategy," aiming to provide sustained contributions to cancer treatment and patient outcomes [23].